Several brokerages have updated their recommendations and price targets on shares of Icon Plc (NASDAQ: ICLR) in the last few weeks:

  • 9/12/2017 – Icon Plc had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $122.00 price target on the stock.
  • 9/11/2017 – Icon Plc is now covered by analysts at Bank of America Corporation. They set a “buy” rating and a $128.00 price target on the stock.
  • 9/9/2017 – Icon Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $131.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 9/7/2017 – Icon Plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 9/1/2017 – Icon Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $126.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 9/1/2017 – Icon Plc was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 8/29/2017 – Icon Plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 8/24/2017 – Icon Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $120.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 8/22/2017 – Icon Plc was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/18/2017 – Icon Plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 7/31/2017 – Icon Plc was upgraded by analysts at SunTrust Banks, Inc. from a “hold” rating to a “buy” rating. They now have a $126.00 price target on the stock, up previously from $93.00.
  • 7/31/2017 – Icon Plc had its “overweight” rating reaffirmed by analysts at KeyCorp.
  • 7/30/2017 – Icon Plc had its “buy” rating reaffirmed by analysts at Jefferies Group LLC.
  • 7/28/2017 – Icon Plc had its “buy” rating reaffirmed by analysts at Credit Suisse Group.
  • 7/27/2017 – Icon Plc had its price target raised by analysts at Mizuho from $104.00 to $108.00. They now have a “neutral” rating on the stock.

Shares of Icon Plc (ICLR) opened at 111.53 on Friday. The firm has a market capitalization of $6.03 billion, a P/E ratio of 22.62 and a beta of 0.61. Icon Plc has a one year low of $73.76 and a one year high of $117.53. The firm’s 50-day moving average is $108.03 and its 200 day moving average is $93.24.

Icon Plc (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.01. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The firm had revenue of $431.00 million for the quarter, compared to analyst estimates of $430.68 million. During the same period in the previous year, the firm earned $1.14 earnings per share. The company’s revenue was up 5.0% compared to the same quarter last year. Equities research analysts predict that Icon Plc will post $5.32 earnings per share for the current year.

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.